Track market-moving stories before they get noisy

July 20, 2026 07:00 ET  | Source: Harrow, Inc.

NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low viscosity ocular anesthetic gel, and BYOOVIZ® (ranibizumab-nuna)i, an FDA-approved biosimilar referencing LUCENTISii (ranibizumab) at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Collectively, the presentations expand the growing body of clinical and real-world evidence supporting Harrow's retina portfolio and reinforce Harrow’s commitment to generating quality evidence that strengthens physician confidence, improves patient experience, and supports long-term product adoption and innovation.

“ASRS is one of the premier scientific meetings in retina, and we're excited to share data that continues to strengthen the foundation supporting our growing retina franchise,” said Mark L. Baum, Chief Executive Officer of Harrow. “We believe durable commercial success is built on strong clinical evidence, generated before FDA-approval, and then robust supportive data sets subsequently produced. These studies further expand the evidence supporting IHEEZO while adding to the growing body of real-world experience for BYOOVIZ, reflecting our long-term commitment to retina specialists and the patients they treat.”

One presentation highlighted interim findings from an investigator-initiated, prospective, randomized study of 150 patients comparing IHEEZO versus subconjunctival lidocaine. While these preliminary data represent an early look at the data, investigators observed encouraging trends toward less post-procedure pain, a better post-injection patient experience, and fewer ocular symptoms through 24 hours following intravitreal injection among patients treated with IHEEZO. Harrow believes these early findings provide an encouraging signal supporting further investigation in a larger patient population.

Importantly, Harrow continues to enroll QUELL, a prospective, randomized, multi-center clinical trial of approximately 236 subjects that is being conducted under an active Investigational New Drug (IND) application. QUELL is designed to generate robust clinical evidence evaluating post-injection pain, patient experience, procedural performance, and safety in a substantially larger patient population, with topline data expected in the fourth quarter of 2026.

Another real-world study retrospectively evaluated whether IHEEZO's proprietary low-viscosity gel formulation interferes with antisepsis when used with chlorhexidine before intravitreal injection. Across nearly 20,000 injections, investigators observed no evidence of an increased endophthalmitis risk compared with a legacy tetracaine/povidone-iodine preparation. Although retrospective and not intended to demonstrate statistical superiority, the findings provide further confidence that physicians can realize the patient-experience benefits of IHEEZO's low-viscosity gel formulation without introducing additional procedural risk associated with antisepsis.

“These studies help build the scientific foundation supporting IHEEZO,” said Amir Shojaei, Chief Scientific Officer of Harrow. “The early interim randomized data suggest the potential to improve the patient experience, while the large real-world analysis provides reassuring evidence regarding procedural safety. We look forward to completing enrollment in QUELL, which we believe will provide the most comprehensive evaluation of IHEEZO in retina to date.”

Finally, Samsung Bioepis presented interim findings from a large-scale, real-world post-marketing surveillance study of BYOOVIZ. Full results from this study are being announced jointly with Samsung Bioepis today.

“Between the continued expansion of the clinical evidence supporting IHEEZO, the recent launch of BYOOVIZ, and the ongoing growth of our retina franchise, we believe Harrow is increasingly well-positioned as a trusted long-term partner to retina specialists,” Baum concluded. “We appreciated the opportunity to engage with physicians throughout ASRS and look forward to sharing additional updates later this year.”

IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, for topical ophthalmic use

INDICATIONS AND USAGE 

IHEEZO is an ester anesthetic indicated for ocular surface anesthesia. 

IMPORTANT SAFETY INFORMATION 

CONTRAINDICATIONS 

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of
this preparation 

WARNINGS AND PRECATIONS 

Not for Injection or Intraocular Administration. Corneal Injury Due to Insensitivity. Corneal Opacification For Administration by Healthcare Provider: IHEEZO is not intended for patient self-administration  ADVERSE REACTIONS 

Most common adverse reaction is mydriasis (approximately 25%) 
Please see full Prescribing information

BYOOVIZ® (ranibizumab-nuna) injection, for intravitreal use is a biosimilar to LUCENTIS (ranibizumab injection) 

INDICATIONS AND USAGE 

BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

Neovascular (Wet) Age-Related Macular Degeneration (AMD)Macular Edema Following Retinal Vein Occlusion (RVO)Myopic Choroidal Neovascularization (mCNV)
 IMPORTANT SAFETY INFORMATION 

 CONTRAINDICATIONS 

Ocular or periocular infectionsHypersensitivity  WARNINGS AND PRECAUTIONS 

Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injectionIncreases in intraocular pressure (IOP) have been noted both pre- and post intravitreal injection There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors 
 ADVERSE REACTIONS 

The most common adverse reactions (reported more frequently in ranibizumab treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP 
 Please see full Prescribing Information 

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contacts:

Mike Biega
Vice President of Investor Relations and Communications
[email protected]
617-913-8890

i Byooviz is a trademark of Samsung Bioepis Co., Ltd.
ii Lucentis is a trademark of Genentech, Inc.

Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar July 01, 2026 07:00 ET  | Source: Harrow, Inc.

NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab) and developed by Samsung Bioepis Co., Ltd.

The launch follows Harrow's exclusive U.S. commercialization agreement with Samsung Bioepis, one of the world's leading biosimilar developers and manufacturers. Through this partnership, Harrow obtained exclusive U.S. rights to commercialize BYOOVIZ and OPUVIZ® (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEAii (aflibercept), further strengthening the Company's position in the rapidly growing retinal biologics market.

BYOOVIZ was approved by the U.S. Food and Drug Administration (FDA) as the first ophthalmology biosimilar in the U.S. for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV). As an FDA-designated interchangeable biosimilar to LUCENTIS, BYOOVIZ provides retina specialists with a clinically proven anti-VEGF therapy that offers confidence, flexibility, and choice in patient care.

The launch of BYOOVIZ marks another important step in the evolution of Harrow's market-leading retina franchise. With an estimated $9 billion U.S. anti-VEGF marketiii and increasing demand for therapies that treat sight-threatening retinal diseases, Harrow continues to build a differentiated portfolio of buy-and-bill products designed specifically for the needs of retina specialists and the patients they serve.

BYOOVIZ joins Harrow's expanding retina franchise, which includes IHEEZO® (chloroprocaine hydrochloride 3% ophthalmic gel), a branded FDA-approved ocular anesthetic indicated for ocular surface anesthesia that is increasingly utilized by retina specialists during intravitreal injection procedures, and TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/ml, a high-trust preservative-free injectable corticosteroid, broadly labeled and increasingly used by retina specialists nationwide. Together, these products enable Harrow to support both the procedural and therapeutic aspects of retinal disease management, providing retina practices with a trusted commercial partner across multiple points of care.

"BYOOVIZ is far more than a product launch—it underscores Harrow's commitment to the U.S. retina community," said Mark L. Baum, Founder, Chairman, and Chief Executive Officer of Harrow. "Over the past several years, we have earned the trust of physicians through products like IHEEZO and TRIESENCE—products a growing number of retina specialists have integrated into their procedural workflows—supported by one of the most experienced and tenured retina teams in the industry. The investments we’ve made in our commercial infrastructure are specifically designed to serve retina specialists, and we intend to keep investing in and growing our retina franchise for years to come. With BYOOVIZ, we will bring our customers an interchangeable ranibizumab biosimilar to a market increasingly focused on both clinical confidence and economic value. Together with exclusive commercialization rights to OPUVIZ in the US, we believe we are creating one of the most compelling retina portfolios in ophthalmology."

“The introduction of BYOOVIZ gives retina specialists another valuable treatment option for our patients,” said Samuel A. Minaker, M.D., vitreoretinal surgeon, Director of Clinical Research at Tyler Retina Consultants. “Many of my patients are treated with LUCENTIS or a LUCENTIS-referenced biosimilar; however, we have found that access to supply has not always been assured, with products coming in and out of availability more recently. What gives me additional confidence in BYOOVIZ is its interchangeability designation, supported by data showing no clinically meaningful differences between the biosimilar and reference product when patients switch between therapies. Just as importantly, it's exciting to see this product return to the market through a commercial partner like Harrow that has already earned credibility in my practice and within the retina community. Harrow understands the needs of retina practices, has demonstrated a commitment to supporting physicians and patients, and brings a level of confidence that makes BYOOVIZ a welcome addition to the treatment options available for my patients.”

“I’ve had the opportunity to work with Harrow on several ophthalmic products,” said Seenu M. Hariprasad, M.D., Chair of Ophthalmology and Visual Science, Chief of Vitreoretinal Service, and Shui-Chin Lee Professor of Ophthalmology and Visual Science at the University of Chicago Medicine. “I first worked with Harrow through IHEEZO, which helped improve the patient experience during intravitreal injection procedures, and later with TRIESENCE, an important treatment option for many patients. Throughout that time, their team has demonstrated an understanding of the clinical, operational, and economic realities retina specialists face every day. Adding BYOOVIZ to their portfolio is a natural extension of that experience. Having access to a trusted ranibizumab biosimilar from a company with experience supporting retina specialists makes BYOOVIZ a welcome addition to the treatment options available for patients.”

Physician Prescribing Information

Healthcare providers interested in prescribing BYOOVIZ (ranibizumab-nuna) for their patients can access prescribing information, patient support resources, and ordering details by visiting https://www.byooviz.com or by calling 1-833-4HARROW (442-7769).

BYOOVIZ® (ranibizumab-nuna) injection, for intravitreal use is a biosimilar to LUCENTIS (ranibizumab injection)

INDICATIONS AND USAGE
BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

Neovascular (Wet) Age-Related Macular Degeneration (AMD)Macular Edema Following Retinal Vein Occlusion (RVO)Myopic Choroidal Neovascularization (mCNV)
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Ocular or periocular infectionsHypersensitivity WARNINGS AND PRECATIONS

Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injectionIncreases in intraocular pressure (IOP) have been noted both pre- and post intravitreal injectionThere is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors
ADVERSE REACTIONS

The most common adverse reactions (reported more frequently in ranibizumab treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP
Please see full Prescribing information

OPUVIZ® (aflibercept-yszy) injection, for intravitreal use is a biosimilar to EYLEA (aflibercept)

INDICATIONS AND USAGE
OPUVIZ is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:

Neovascular (Wet) Age-Related Macular Degeneration (AMD)Macular Edema Following Retinal Vein Occlusion (RVO)Diabetic Macular Edema (DME)Diabetic Retinopathy (DR) IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Ocular or periocular infectionsActive intraocular inflammationHypersensitivity
WARNINGS AND PRECATIONS

Endophthalmitis, retinal detachments, and retinal vasculitis with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.
ADVERSE REACTIONS

The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
Please see full Prescribing information

IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3%, for topical ophthalmic use

INDICATIONS AND USAGE

IHEEZO is an ester anesthetic indicated for ocular surface anesthesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation WARNINGS AND PRECATIONS

Not for Injection or Intraocular Administration.Corneal Injury Due to Insensitivity.Corneal OpacificationFor Administration by Healthcare Provider: IHEEZO is not intended for patient self-administration ADVERSE REACTIONS

Most common adverse reaction is mydriasis (approximately 25%)
Please see full Prescribing information

TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL

INDICATIONS AND USAGE
TRIESENCE® Suspension is indicated for:

Treatment of the following ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.Visualization during vitrectomy. IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

TRIESENCE® Suspension is contraindicated in patients with systemic fungal infections.TRIESENCE® Suspension is also contraindicated in patients with hypersensitivity to corticosteroids or any component of TRIESENCE® Suspension. Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy. WARNINGS AND PRECATIONS

TRIESENCE® is a suspension; it should not be administered intravenously.Ophthalmic effects: May include cataracts, infections, and glaucoma. Monitor intraocular pressure.Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome and hyperglycemia: Monitor patients for these conditions and taper doses gradually.Infections: Increased susceptibility to new infection and increased risk of exacerbation, dissemination, or reactivation of latent infection.Elevated blood pressure, salt and water retention, and hypokalemia: Monitor blood pressure and sodium, potassium serum levels.GI perforation: Increased risk in patients with certain GI disorders.Behavioral and mood disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis.Decreases in bone density: Monitor bone density in patients receiving long term corticosteroid therapy.Live or live attenuated vaccines: Do not administer to patients receiving immunosuppressive doses of corticosteroids.Negative effects on growth and development: Monitor pediatric patients on long-term corticosteroid therapy.Use in pregnancy: Fetal harm can occur with first trimester use.Weight gain: May cause increased appetite. ADVERSE REACTIONS

Based on a review of the available literature, the most commonly reported adverse events following ocular administration of triamcinolone acetonide were elevated intraocular pressure and cataract progression. These events have been reported to occur in 20-60% of patients.Less common reactions occurring in up to 2% of patients include: endophthalmitis (infectious and non-infectious), hypopyon, injection site reactions (described as blurring and transient discomfort), glaucoma, vitreous floaters, detachment of retinal pigment epithelium, optic disc vascular disorder, eye inflammation, conjunctival hemorrhage and visual acuity reduced. Cases of exophthalmos have also been reported. Please see full Prescribing information

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology and neurology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contacts:

Mike Biega
Vice President of Investor Relations and Communications
[email protected]
617-913-8890

i Lucentis is a trademark of Genentech, Inc.
ii Eylea is a trademark of Regeneron Pharmaceuticals, Inc
iii Emergen Research, U.S. Anti-VEGF Market Size, Growth Outlook 2034

Key Takeaways HROW shares rose after relaunching Verkazia, an FDA-approved eye drop for vernal keratoconjunctivitis.Harrow relaunched Verkazia to improve supply, access and support for physician prescribing.Verkazia is the first FDA-approved nonsteroidal therapy specifically indicated for VKC. Shares of Harrow (HROW - Free Report) rose 7.3% on June 10, 2026, after the company relaunched Verkazia (cyclosporine ophthalmic emulsion) 0.1% in the United States. Verkazia is an FDA-approved steroid-sparing eye drop for the treatment of patients with vernal keratoconjunctivitis (VKC).

VKC is a chronic inflammatory eye disease that primarily affects children and can lead to severe symptoms, including itching, pain, light sensitivity and corneal damage. The condition often persists for years, significantly affecting quality of life, daily activities and development, while treatment options have historically been limited, especially for pediatric patients.

Year to date, Harrow shares have lost 26.8% compared with the industry’s 9.9% decline.

Image Source: Zacks Investment Research

Rationale Behind the Relaunching of HROW’s VerkaziaThe relaunch of Verkazia aimed to address longstanding access and supply challenges that have limited the availability of this FDA-approved therapy for patients with VKC. Despite the drug's established clinical efficacy, many patients have faced difficulties obtaining consistent treatment. Harrow reintroduced Verkazia to ensure a dependable supply chain, improve patient access and support physicians in prescribing a proven steroid-sparing therapy for a disease that remains significantly underdiagnosed and underserved, particularly among pediatric patients requiring long-term management.

Management described Verkazia as the second of three priority products that Harrow is commercializing as part of its broader ophthalmology growth plan.

In pediatric VKC, antihistamines often fail to control the underlying inflammation, forcing reliance on corticosteroids as the primary treatment despite their long-term risks. Verkazia was developed to address this unmet need. As the first FDA-approved nonsteroidal therapy specifically indicated for VKC, it offers a targeted approach to controlling the disease's underlying inflammatory mechanisms.

HROW’s Zacks Rank & Stocks to ConsiderHarrow currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) , Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings estimates for Indivior Pharmaceuticals were unchanged at $4.05 per share for 2026 and $4.27 for 2027. INDV shares have risen 6.1% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in the trailing four quarters, the average surprise being 65.44%.

Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.94. Over the same period, EPS estimates for 2027 have risen to $4.81 from $3.79. LQDA shares have gained 89.2% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 54.40%.

Over the past 30 days, earnings estimates for Immunocore’s 2026 were unchanged at 6 cents per share for 2026 and 87 cents for 2027. IMCR shares have lost 19.6% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.

March 24, 2026 08:15 ET  | Source: Harrow, Inc.

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company’s existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The 2030 Notes will be issued as additional notes under the same indenture governing the $250,000,000 aggregate principal amount of 2030 Notes that were issued on September 12, 2025 (the “Existing Notes”), will be treated as a single series with the Existing Notes and will have the same terms as the Existing Notes other than with respect to the date of issuance and the issue price.

Harrow intends to use the net proceeds from this incremental issuance for general corporate purposes, which may include initiatives to accelerate growth (e.g., new product launches), funding upcoming product development activities, future strategic business development opportunities, and related investments.

The 2030 Notes and the related guarantees have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), any state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States, or for the benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities or blue sky laws. Accordingly, the 2030 Notes and the related guarantees are being offered only to persons reasonably believed to be “qualified institutional buyers,” as that term is defined under Rule 144A of the Securities Act, or outside the United States to non-“U.S. persons” in accordance with Regulation S under the Securities Act.

A confidential offering memorandum for the Offering, dated as of today, is being made available to such eligible persons. The Offering is being conducted in accordance with the terms and subject to the conditions set forth in such confidential offering memorandum.

This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer, or solicitation to buy, if at all, will be made only by means of a confidential offering memorandum.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, including, without limitation, statements regarding the Offering and the expected use of proceeds therefrom. These statements are based on currently available operating, financial, economic and other information, and are subject to a number of significant risks and uncertainties. A variety of factors, many of which are beyond our control, could cause actual future results to differ materially from those projected in the forward-looking statements. Specific factors that might cause such a difference include, but are not limited to: changes in market conditions, negotiation of final transaction documents, changes in operations, business, financial or other conditions relevant to the planned transactions, and other execution risks related to the completion of the transactions described herein, as well as other risks detailed in our most recent annual report on Form 10-K and other filings with the Securities and Exchange Commission. We believe these forward-looking statements are reasonable; however, you should not place undue reliance on any forward-looking statements, which are based on current expectations. Furthermore, forward-looking statements speak only as of the date they are made. If any of these risks or uncertainties materialize, or if any of our underlying assumptions are incorrect, we may not be able to complete the potential transactions on terms expected or at all, and our actual results may differ significantly from those expected or implied by our forward-looking statements. These and other risks are detailed in our filings with the Securities and Exchange Commission. We do not undertake any obligation to publicly update or revise these forward-looking statements after the date of this press release to reflect future events or circumstances, except as required by applicable law. We qualify any and all of our forward-looking statements by these cautionary factors.

Contact:

Mike Biega
Vice President of Investor Relations and Communications
[email protected] 
617-913-8890

March 24, 2026 16:57 ET  | Source: Harrow, Inc.

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the “2030 Notes”). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company’s existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The Offering is expected to close on March 27, 2026, subject to customary closing conditions.

The $50.0 million aggregate principal amount of 2030 Notes will be issued as additional notes under the same indenture governing the $250,000,000 aggregate principal amount of 2030 Notes that were issued on September 12, 2025 (the “Existing Notes”) and will be treated as a single series with the Existing Notes and will have the same terms as the Existing Notes, other than with respect to the date of issuance and the issue price.   The 2030 Notes bear interest at a rate of 8.625% per annum and will mature on September 15, 2030. Interest on the 2030 Notes will be payable semi-annually in cash in arrears on March 15 and September 15 of each year. Interest on the 2030 Notes will be deemed to have accrued from March 15, 2026, which was the last interest payment date for the Existing Notes, and will be payable beginning on September 15, 2026. The $50.0 million aggregate principal amount of 2030 Notes will be issued at an offering price of 100.25% of the principal amount thereof plus accrued interest from March 15, 2026.

Harrow intends to use the net proceeds from this incremental issuance for general corporate purposes, which may include initiatives to accelerate growth (e.g., new product launches), funding upcoming product development activities, future strategic business development opportunities, and related investments.

The 2030 Notes and the related guarantees have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), any state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States, or for the benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities or blue sky laws. Accordingly, the 2030 Notes and the related guarantees are being offered only to persons reasonably believed to be “qualified institutional buyers,” as that term is defined under Rule 144A of the Securities Act, or outside the United States to non-“U.S. persons” in accordance with Regulation S under the Securities Act.

A confidential offering memorandum for the Offering, dated as of today, is being made available to such eligible persons. The Offering is being conducted in accordance with the terms and subject to the conditions set forth in such confidential offering memorandum.

This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer, or solicitation to buy, if at all, will be made only by means of a confidential offering memorandum.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, including, without limitation, statements regarding the Offering and the expected use of proceeds of the Offering. These statements are based on currently available operating, financial, economic and other information, and are subject to a number of significant risks and uncertainties. A variety of factors, many of which are beyond our control, could cause actual future results to differ materially from those projected in the forward-looking statements. Specific factors that might cause such a difference include, but are not limited to: changes in market conditions, negotiation of final transaction documents, changes in operations, business, financial or other conditions relevant to the planned transactions, and other execution risks related to the completion of the transactions described herein, as well as other risks detailed in our most recent annual report on Form 10-K and other filings with the Securities and Exchange Commission. We believe these forward-looking statements are reasonable; however, you should not place undue reliance on any forward-looking statements, which are based on current expectations. Furthermore, forward-looking statements speak only as of the date they are made. If any of these risks or uncertainties materialize, or if any of our underlying assumptions are incorrect, we may not be able to complete the potential transactions on terms expected or at all, and our actual results may differ significantly from those expected or implied by our forward-looking statements. These and other risks are detailed in our filings with the Securities and Exchange Commission. We do not undertake any obligation to publicly update or revise these forward-looking statements after the date of this press release to reflect future events or circumstances, except as required by applicable law. We qualify any and all of our forward-looking statements by these cautionary factors.

Contact:
Mike Biega
Vice President of Investor Relations and Communications
[email protected]
617-913-8890

On April 13, 2026, Harrow Inc HROW shares rose 3.3% to a current price of $37.10. This price movement is situated within a 52-week range of $21.12 to $54.85, indicating notable volatility over the past year.

GF Value™ verdict: HROW is currently priced at $37.10, which is 18.4% below the GF Value™ estimate of $45.49.GF Score™ is 86/100, which suggests strong potential for long-term returns based on the stock's underlying fundamentals.Most notable signal: Insiders sold $8.1 million in HROW stock over the last three months, indicating a lack of confidence from those closest to the company. Is HROW Overvalued or Undervalued? Evaluating Harrow Inc's current price in relation to its GF Value™, the stock appears to be undervalued by 18.4% based on the GF Value™ estimate of $45.49. This margin of safety presents a potential opportunity for investors seeking stocks with a favorable risk-reward profile. Furthermore, the GF Valuation label classifies HROW as "Modestly Undervalued," which supports the notion that the stock could be priced lower than its intrinsic value. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

However, investors should be cautious, as the financial strength rating of 4/10 indicates some vulnerability, and the prediction model shows only 1 star for predictability. These factors suggest that, while there is an opportunity for upside, there are also risks involved, particularly if the company faces operational challenges or market fluctuations in the near term.

How Does HROW's Valuation Compare to Its History? MetricCurrentHistorical P/E (TTM)77.3x30.3x Harrow Inc's current forward P/E of 77.3x is significantly higher than its 5-year median P/E of 30.3x. This suggests that the stock is trading above its historical valuation metrics. The P/E analysis indicates an inconsistency with the GF Value™ verdict, as a higher P/E typically signifies overvaluation in relation to historical performance. Investors may want to consider this discrepancy when assessing the stock's future potential.

What Does HROW's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021).

MetricRating GF Score™86 Financial Strength4/10 Profitability5/10 Growth10/10 Valuation8/10 Momentum8/10 Harrow Inc’s GF Score™ of 86/100 reflects strong growth potential, with a perfect growth rank of 10/10 and solid valuation rank of 8/10. However, the financial strength score of 4/10 highlights a weakness that may raise concerns about the company's stability. Overall, while HROW exhibits promising growth and valuation metrics, its financial strength could be a limiting factor in its long-term performance.

What Are Insiders Doing with HROW Stock? In the past three months, insiders at Harrow Inc have sold $8.1 million worth of shares without making any purchases. This pattern of selling can often be interpreted as a signal of lack of confidence in the company's future performance, which may warrant caution for potential investors. Insider selling can indicate that those with the most knowledge about the company believe that the stock may not be a favorable investment at current levels.

What This Means for Investors Based on the GF Value™ assessment, Harrow Inc HROW is currently undervalued. However, investors must weigh this opportunity against the potential risks indicated by weak financial strength and significant insider selling. The overall outlook suggests a need for careful monitoring of the company's operational performance and market environment.

For the complete analysis, visit the Harrow Inc HROW stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is HROW's GF Score™?

HROW's GF Score™ is 86/100, which indicates a strong potential for long-term returns based on the stock's fundamentals.

Is HROW overvalued or undervalued?

HROW is considered undervalued, with its current price of $37.10 being 18.4% below the GF Value™ estimate of $45.49.

What is HROW's P/E ratio?

HROW's current forward P/E is 77.3x, which is significantly above its historical 5-year median P/E of 30.3x, indicating it is trading at a higher valuation compared to its past performance.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

, /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic disease management solutions. Effective February 1, 2026, LogiCare3PL is providing both non-title and 3PL title distribution services, supporting distribution of Harrow's products across the U.S. market.

LogiCare3PL was selected for its high-touch service model, proven ability to execute quickly and efficiently, and commitment to building a long-term partnership. These capabilities were essential in supporting Harrow's need for rapid onboarding and market readiness.

This partnership enables faster, more cost-effective market access for Harrow's products, while maintaining a high level of engagement and support from the LogiCare3PL team. LogiCare3PL successfully onboarded Harrow within just four weeks, meeting Harrow's implementation timeline and ensuring business continuity.

Kevin Kissling, VP/GM 3PL Services for LogiCare3PL, commented: "We are proud to partner with Harrow and support their broad portfolio of ophthalmic disease management solutions. At LogiCare3PL, we are committed to delivering on every promise we make and developing solutions that meet each manufacturer's specific needs. Harrow and LogiCare3PL's shared focus on flexibility, customer-centricity, and rapid execution makes this collaboration especially meaningful."

The agreement, effective February 1, 2026, covers LogiCare3PL's full suite of 3PL services, including non-title logistics support and title distribution for Harrow's products. Both organizations anticipate continued collaboration as Harrow expands its product offerings.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

About LogiCare3PL
LogiCare3PL, a BioCare company, is a trusted pharmaceutical third‑party logistics partner serving emerging and mid‑sized biopharmaceutical manufacturers. Specializing in specialty, rare, and ultra‑rare disease therapies, LogiCare3PL delivers tailored, end‑to‑end solutions including time‑ and temperature‑sensitive logistics, centralized warehousing, financial services, regulatory compliance and licensing support, advanced data analytics, and comprehensive manufacturer and customer care. Through an integrated, compliant, and reliable approach, LogiCare3PL ensures products move securely from manufacturer to market. With unmatched reliability and expertise, LogiCare3PL sets the standard for precision and trust in pharmaceutical logistics.

Media Contact:
BioCare, Inc.

Barbara Pantazopoulos
VP Marketing & Communications
[email protected]
biocare-us.com  

SOURCE LogiCare3PL

Harrow has delivered a decade-long 40% CAGR in revenue, with robust operating leverage and EBITDA margin expansion. Seasonal weakness in Q1 consistently creates compelling entry points, with share prices typically bottoming near the Q1 report date and rebounding sharply later in the year. HROW's 2026 low of $33 suggests a likely move to $100 within the year, reflecting the historical pattern of annual highs being about 3x annual lows.

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 12, 2026 April 27, 2026 07:00 ET  | Source: Harrow, Inc.

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the first quarter ended March 31, 2026, on Monday, May 11, 2026, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 12, 2026, to discuss the results and provide a business update.

Conference Call Information
Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.

To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact:
Mike Biega
VP of Investor Relations & Communications
[email protected]
617-913-8890

May 11, 2026 16:05 ET  | Source: Harrow, Inc.

First Quarter 2026 and Selected Highlights: 

VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category)VEVYE demand growth on track to deliver 2026 revenue of over $100 millionQuarterly revenue of $44.2 million, including a non-recurring gross-to-net revenue adjustment connected to new VEVYE commercial coverage, which lowered Q1 revenue by approximately $8 millionIHEEZO® unit demand increased 18% year-over-year, with 82% of units from retina accountsTRIESENCE® unit demand more than doubled year-over-year, the sixth consecutive quarter of growthSecond Quarter revenue expected between $71 million and $81 millionFull-year 2026 revenue guidance reaffirmed at $350 million to $365 millionCash and cash equivalents of $94.6 million as of March 31, 2026 A Media Snippet accompanying this announcement is available by clicking on this link.

NASHVILLE, Tenn., May 11, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the first quarter ended March 31, 2026. The Company also posted its first-quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website at harrow.com. The Company encourages Harrow stockholders to review these documents, which provide additional details concerning the historical results and future expectations for the business.

“The demand for Harrow’s key products has never been stronger, and our visibility into our demand trajectory – across our portfolio – keeps us entirely on track to reach our forecasted financial goals for the year,” said Mark L. Baum, Chief Executive Officer of Harrow. “Although our first-quarter reported revenue reflects an estimated $8 million gross-to-net reduction associated with our new commercial coverage for VEVYE, this adjustment does not reflect the profitable, recurring, and significant patient base established during the quarter. Harrow is now positioned to realize the full financial benefits of this coverage relationship beginning in Q2 2026.”

Baum continued, “Prior to the quarter, we established business rules with specific assumptions regarding these new VEVYE commercial patients. As the period unfolded, the surge in demand among patients with high-deductible plans significantly outpaced our initial models. This created temporary gross-to-net pressure, which was resolved through business rules adjustments. With these rules now in place, we are now positioned to realize the expected financial benefit of our expanded commercial access, and we are already seeing highly encouraging net pricing indicators early in the second quarter.”

“Our core commercial engine is accelerating. VEVYE delivered record prescription performance and has officially surpassed XIIDRA on a monthly total prescription basis. Across our key growth drivers - VEVYE, IHEEZO, and TRIESENCE - we are seeing robust prescriber adoption, expanding market share, and durable momentum. With our expanded commercial organization now fully deployed, we remain highly confident in our ability to deliver on our 2026 revenue guidance of $350 million to $365 million.”

Key First Quarter Demand Indicators:

VEVYE:

Prescription growth of approximately 170% sequentially within our new national pharmacy benefit manager’s Tier 1 accountsRecord quarterly prescription performance, with NRx up 25% and TRx up 11% quarter-over-quarter, despite a decline in the overall branded dry eye marketSurpassed XIIDRA on a monthly TRx basis, achieving approximately 14% market share as of the end of March 2026 IHEEZO:

Unit demand increased 18% year-over-year, with March 2026 up 34% versus the prior-year periodRetina accounts represented approximately 82% of total volume, reflecting continued strength in the core marketOrdering accounts continued to expand, driven by growing adoption across both retina and in-office procedural settings TRIESENCE:

Unit demand more than doubled year-over-year, increasing 136% versus the prior-year periodSixth consecutive quarter of growth, supported by continued expansion of the customer base, including 195 new accounts in the quarter, representing approximately 28% of total ordering accounts First Quarter 2026 Financial Results:

 For the Three Months Ended
March 31, 2026
 2025
Total revenues$        44,203,000  $        47,831,000 Gross margin 61%  68%Net loss    (27,602,000)  (17,780,000)Adjusted EBITDA(1) (12,659,000)  (1,985,000)Net loss per share, basic and diluted (0.74)  (0.50)         (1)   Adjusted EBITDA is a non-GAAP measure. For additional information, including a reconciliation of Adjusted EBITDA to the most directly comparable measure presented in accordance with GAAP, see the explanation of non-GAAP measures and reconciliation tables at the end of this release.

Conference Call and Webcast

Harrow will host a conference call to discuss the results at 8:00 a.m. ET on Tuesday, May 12, 2026.   Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.

To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, to access the call.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward--looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking- statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking- statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact:
Mike Biega, VP of Investor Relations and Communications
[email protected]
617-913-8890

HARROW, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
 March 31,
2026 December 31,
2025    ASSETSCash and cash equivalents$94,644,000 $72,927,000All other current assets 131,740,000  138,823,000Total current assets 226,384,000  211,750,000All other assets 193,159,000  187,732,000TOTAL ASSETS$419,543,000 $399,482,000    LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities$91,439,000 $96,302,000Loans payable, net of unamortized debt discount 292,087,000  243,184,000All other liabilities 7,666,000  7,905,000TOTAL LIABILITIES 391,192,000  347,391,000TOTAL STOCKHOLDERS' EQUITY 28,351,000  52,091,000TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$419,543,000 $399,482,000       HARROW, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
   For the Three Months Ended
March 31, 2026
 2025
Total revenues$44,203,000  $47,831,000 Cost of sales (17,158,000)  (15,524,000)Gross profit 27,045,000   32,307,000 Selling, general and administrative 43,230,000   40,513,000 Research and development 5,895,000   3,026,000 Total operating expenses 49,125,000   43,539,000 Loss from operations (22,080,000)  (11,232,000)Interest expense, net (5,497,000)  (6,548,000)Income tax expense (25,000)  - Net loss$(27,602,000) $(17,780,000)Net loss per share:   Basic and diluted$(0.74) $(0.50)         HARROW, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
  For the Three Months Ended
March 31,2026
 2025
Net cash provided by (used in):   Operating activities$        (8,992,000) $        19,668,000 Investing activities (18,203,000)  (212,000)Financing activities 48,912,000   23,000 Net change in cash and cash equivalents 21,717,000   19,479,000 Cash and cash equivalents at beginning of the period 72,927,000   47,247,000 Cash and cash equivalents at end of the period$        94,644,000  $        66,726,000          Non-GAAP Financial Measures
In addition to the Company’s results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP), which are presented and discussed above, management also utilizes Adjusted EBITDA, an unaudited financial measure that is not calculated in accordance with GAAP, to evaluate the Company’s financial results and performance and to plan and forecast future periods. Adjusted EBITDA is considered a “non-GAAP” financial measure within the meaning of Regulation G promulgated by the SEC. Management believes that this non-GAAP financial measure reflects an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results, provides a more complete understanding of the Company’s results of operations and the factors and trends affecting its business. Management believes Adjusted EBITDA provides meaningful supplemental information regarding the Company’s performance because (i) it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making; (ii) it excludes the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that may obscure trends in the Company’s core operating performance; and (iii) it is used by institutional investors and the analyst community to help analyze the Company’s results. However, Adjusted EBITDA, and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the Company and the way they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies, including the Company’s competitors.

Adjusted EBITDA
The Company defines Adjusted EBITDA as net income (loss), excluding the effects of stock-based compensation and expenses, impairment of intangible assets, interest, taxes, depreciation, amortization, investment loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net income (loss) as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs.

The following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net income (loss), for the three months ended March 31, 2026 and for the same period in 2025:

HARROW, INC.
RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA
   For the Three Months Ended
March 31, 2026
 2025
GAAP net loss$(27,602,000) $(17,780,000)Stock-based compensation and expenses 3,837,000   4,556,000 Interest expense, net 5,497,000   6,548,000 Income tax expense 25,000   - Depreciation 455,000   465,000 Amortization of intangible assets 5,129,000   4,226,000 Adjusted EBITDA$(12,659,000) $(1,985,000)

Harrow NASDAQ: HROW executives said the company’s first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized that underlying demand for its core ophthalmic products is accelerating.

On the company’s first-quarter 2026 earnings call, CEO Mark L. Baum said the quarter’s headline revenue figure reflected “a specific isolated dynamic” rather than a deterioration in demand. Harrow reported consolidated revenue of $44.2 million and adjusted EBITDA of negative $12.7 million for the quarter, according to President and Chief Financial Officer Andrew Boll.

Get Harrow alerts:

“The underlying fundamentals of Harrow have never been stronger,” Baum said, adding that demand for the company’s key growth drivers is “at or above” internal expectations.

VEVYE Revenue Hit by Gross-to-Net Issue Management said VEVYE generated approximately $20.9 million in first-quarter revenue, but that reported revenue was reduced by about $8 million due to a gross-to-net modeling issue related to expanded commercial coverage that began Jan. 1.

Boll said Harrow’s initial business rules assumed a certain patient mix and level of out-of-pocket support. While January results tracked with expectations, the company later saw a significantly higher proportion of high-deductible patients filling prescriptions through pharmacy benefits, increasing average out-of-pocket buydowns and pressuring net revenue per unit.

“Due to the standard industry lag in claims reporting, the full magnitude of this mix shift was confirmed in mid-April,” Boll said. He said Harrow then implemented targeted changes, including strict caps on co-pay buydowns and other refinements intended to protect net pricing.

In response to an analyst question, Boll said CVS-covered patients were coming in about 40% higher on out-of-pocket buydown amounts than other covered patients. He said the business rule changes should move those patients from being, on average, “negative revenue” to “much more positive” contributors going forward.

Baum said the changes have shown “negligible impact” on new prescription demand. He said recent VEVYE prescription data showed “higher highs and higher lows,” which he attributed in part to the company’s expanded sales force beginning to affect field activity.

Company Reaffirms 2026 Guidance Despite the first-quarter adjustment, Harrow reaffirmed full-year 2026 revenue guidance of $350 million to $365 million. Boll said the company expects second-quarter revenue of $71 million to $81 million, with VEVYE showing sequential growth.

Management also reiterated its expectation that VEVYE will exceed $100 million in revenue for the year. Boll said April trends suggested net pricing is “much better aligned” with internal expectations and should be notably higher than in the first quarter. In response to a question on average selling prices, Boll said assuming the current setup, a roughly 30% increase was a reasonable assumption.

Baum said Harrow’s commercial investments, including the hiring of more than 90 new sales professionals, are now complete. The company doubled its VEVYE dry eye sales force, expanded its surgical and retina-related teams, and added resources for Access+ and specialty products.

Pat Sullivan, Harrow’s chief commercial officer, said VEVYE new prescriptions grew approximately 25% sequentially in the quarter, while total prescriptions grew about 11%. He said the prescriber base expanded another 12% sequentially, and the product exited March with roughly 14% branded share, surpassing Xiidra on a monthly total prescription basis.

IHEEZO, TRIESENCE and Other Products IHEEZO contributed $1.9 million in first-quarter revenue, which Boll said was in line with expectations as channel inventory was absorbed. Sullivan said IHEEZO unit demand grew 18% year over year, new ordering accounts increased by 21 during the quarter, and total accounts were up nearly 50% from last year. Retina procedures represented more than 80% of volume.

Harrow expects IHEEZO revenue to begin rebounding in the second quarter but remain below prior-year levels due to channel dynamics, Boll said. He said results should move toward a more normalized level in the third and fourth quarters, helped by a new multi-unit package launching in July and an expected 20% to 25% improvement in net pricing beginning in the second half.

Baum said the ambulatory surgery center business for IHEEZO is expected to “go to zero” following the loss of pass-through reimbursement, but he said the company expects to replace prior ASC unit volumes with in-office use cases by the end of the year. He described in-office coverage as “nearly pervasive,” with better than 95% coverage and a prior authorization rate below 5%.

TRIESENCE delivered $7.8 million in first-quarter revenue. Sullivan said the product posted 136% year-over-year unit volume growth, with March up 113% from a year earlier. He said TRIESENCE has now recorded six consecutive quarters of demand growth, with unit demand up roughly 250% over that period. Harrow also said its label expansion study in cataract surgery and pain is underway.

Access+ revenue was $13.5 million. Baum and Sullivan said Harrow had worked through prior inventory constraints in the cash-pay business and rebuilt inventory for key products.

Second-Half Catalysts and New Launches Boll said the company expects a stronger second half supported by several catalysts, including full deployment of the expanded VEVYE sales force, better VEVYE net pricing, the July 1 commercial launch of BYOOVIZ, and the July 1 effective date of a permanent J-code for IOPIDINE 1%.

Sullivan said IOPIDINE is the only FDA-approved therapy to prevent intraocular pressure spikes following various in-office procedures. He said the permanent J-code, reimbursed at ASP plus 6%, changes the economics for physicians and could unlock an addressable market of more than 1.5 million annual laser procedure use cases. Baum said IOPIDINE is expected to be an incremental contributor in the second half of 2026, with a larger impact expected in 2027.

Baum also said BYQLOVI samples are already being distributed to select customers, while the trade launch, meaning revenue-generating sales, is expected to begin in the third quarter. He said Harrow’s full-year guidance includes BYQLOVI, though the company is not providing product-specific revenue expectations for BYQLOVI or BYOOVIZ.

MELT-300 Development Remains on Track Chief Scientific Officer Amir Shojaei discussed MELT-300, Harrow’s IV- and opioid-free procedural sedation candidate acquired from Melt Pharmaceuticals. He said the company has initiated required pharmacokinetic and non-clinical toxicology studies. The non-clinical study is in the reporting phase, and the first pharmacokinetic study has been completed and is in clinical study report drafting.

Shojaei said renal and hepatic impairment studies are underway, with final reports anticipated in the fourth quarter of 2026. He also said a major manufacturing campaign scheduled for later in the quarter is expected to support the data package required for an NDA submission. Baum later said investors should think about a first-quarter 2027 submission, though he said Harrow would provide more information on the next quarterly call.

In closing, Baum said the first-quarter issue was resolved and did not change the company’s long-term trajectory. “We’re now entering a period where the foundation translates into sustained revenue growth and increasing profitability,” he said.

About Harrow NASDAQ: HROWHarrow Health, Inc NASDAQ: HROW is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Harrow Right Now?Before you consider Harrow, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.

While Harrow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the company advised that VEVYE revenue of $20.9 million during the first quarter of 2026 was below expectations due to an estimated $8 million gross-to-net reduction associated with new commercial coverage for VEVYE.

Upon this news, HROW’s stock price fell 23.69% in trading on May 12, 2026. In particular, on HROW’s quarterly earnings call on May 12, 2026, several analysts inquired into the gross-to-net adjustment.

If you are or were a HROW shareholder and have suffered losses, you may contact us at the following link to discuss your legal rights and options at no charge:

https://wohlfruchter.com/cases/harrow/

Alternatively, you may contact us by phone at 866-833-6245, or via email at [email protected].

About Wohl & Fruchter
Wohl & Fruchter LLP, with offices in New York City and Monsey, has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.

Contact:
Wohl & Fruchter LLP
Joshua E. Fruchter
Toll Free 866.833.6245
[email protected]
www.wohlfruchter.com

June 10, 2026 07:00 ET  | Source: Harrow, Inc.

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriersVERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children and may lead to sight-threatening conditions if left untreated or undertreatedVERKAZIA is a calcineurin inhibitor immunomodulator that targets the underlying inflammatory mechanisms of VKC and may reduce the need for steroid rescue, all of which are associated with risks such as glaucoma or cataract formation
NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy indicated for the treatment of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children.

“The re-launch of VERKAZIA underscores our commitment to advancing care in underserved ophthalmic conditions,” said Mark L. Baum, Chief Executive Officer of Harrow. “As outlined in our recent Letter to Stockholders, VERKAZIA is the second of three priority products within our portfolio that we are actively executing against. VKC is a clinically significant, yet highly underdiagnosed disease, affecting a vulnerable patient population, where the central challenge has not been clinical efficacy, but consistent access to therapy. Our focus with this re-launch is straightforward: ensure dependable supply, remove access barriers, and enable physicians and patients to reliably obtain this important, evidence-based, and, most importantly, steroid-sparing treatment, for long-term disease management.”

“Vernal keratoconjunctivitis is more than a seasonal allergy—it is a chronic inflammatory disease that can meaningfully disrupt a child’s daily life and long-term ocular health,” said Dr. Angela Zhu, M.D., Pediatric Ophthalmologist at Bascom Palmer Eye Institute. “Targeted therapies like VERKAZIA that address the underlying immune response are essential to improving both symptom control and disease trajectory.”

“There remains a substantial need for effective, long-term VKC treatment options, particularly those that reduce steroid exposure,” said Dr. Elsa Sheerer, OD., Pediatric Optometrist at NYC Health + Hospitals. “The availability of a targeted cyclosporine formulation is an important advancement for clinicians managing this complex disease.”

VKC is a chronic, potentially sight-threatening condition perpetuated by significant ocular inflammation, often resulting in severe itching, pain, photophobia, and, in some cases, corneal damage. The disease typically begins in early childhood and may persist for years—often through adolescence—with seasonal exacerbations and, in some cases, continuation into adulthood. VKC has been shown to significantly impact quality of life, affecting school performance, outdoor activity, sleep, and social development—often disproportionately to clinical severity. Despite its meaningful clinical burden and impact on quality of life, treatment options for VKC—particularly in pediatric populations—have historically been limited.

Pediatric patients are typically initiated on antihistamines; however, approximately 61% of VKC patients are inadequately controlled on antihistamines alone.i When antihistamines fail to provide sufficient relief, clinicians have historically turned to corticosteroids—but chronic steroid use in children carries significant risks, including glaucoma and cataract formation. Prior to VERKAZIA, no FDA-approved steroid-sparing therapy existed for VKC, leaving a substantial gap in care for both mild and severe patients.

VERKAZIA is a topical calcineurin inhibitor immunomodulator that targets the underlying inflammatory mechanisms of VKC. Consensus guidelines increasingly support the early use of calcineurin inhibitors to control inflammation, reduce reliance on corticosteroids, and improve long-term outcomesii. Unlike chronic steroid use, VERKAZIA does not carry risks such as glaucoma or cataract formation, making it particularly important in pediatric populations.

In randomized, controlled clinical trials, VERKAZIA demonstrated statistically significant improvements in corneal damage (keratitis), meaningful reductions in hallmark symptoms such as itching, photophobia, and tearing, and decreased need for corticosteroid rescue therapy compared to control—supporting its role as a foundational, steroid-sparing therapy for long-term VKC management.iii

From a market perspective, VKC represents a durable and underdiagnosed segment within ophthalmology, with increasing clinical awareness and a growing emphasis on early, disease-modifying treatment. The condition’s chronicity, pediatric onset, and need for long-term management contribute to sustained demand for safe, well-tolerated therapies.

Harrow’s re-launch of VERKAZIA is supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives, with the goal of improving diagnosis, treatment adoption, and continuity of care.

Clinicians seeking to prescribe VERKAZIA can contact 1-833-4HARROW (1-833-442-7769) or at this link. Additional product details can be found on the product website.

VERKAZIA®
(cyclosporine ophthalmic emulsion) 0.1%

Indications and Usage
Verkazia® (cyclosporine ophthalmic emulsion) 0.1% is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis in children and adults.

Important Safety information

WARNINGS AND PRECAUTIONS
Potential for eye injury and contamination: To avoid the potential for eye injury and contamination, advise patient not to touch the vial tip to the eye or other surfaces.

ADVERSE REACTIONS
The most common adverse reactions reported in greater than 5% of patients were eye pain (12%) and eye pruritus (8%), which were usually transitory and occurred during instillation.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contacts:

Mike Biega
Vice President of Investor Relations and Communications
[email protected]
617-913-8890

i Ophthalmology, 2024 — Steroids Dominate Treatment of VKC
ii VKC Consensus Statement 2023
iii VERKAZIA Clinical Data